Earnings Roundup: Specialty/Smaller Biopharmas See Modest Hit From Pandemic
Executive Summary
First quarter financials and COVID-19 impacts from Bausch, Neurocrine, Theravance, Ironwood, Rigel.
You may also be interested in...
Coronavirus Update: J&J Vaccine On Pause Amid Reports Of Clots
The CDC and FDA recommended a pause on dosing of J&J's one-shot vaccine. Pfizer/BioNTech's vaccine showed signs of lower efficacy against the B.1.351 variant, but a prominent expert called the data "misleading." Gilead halted its Phase III study of Veklury in non-hospitalized, high-risk patients. And Rigel's Tavalisse may have a shot in the sickest COVID-19 patients despite the small size of a Phase II study.
Neurocrine Will Delay Ongentys Launch, But It Thinks Differentiation Is Clear
Ongentys, now approved as adjunctive therapy in Parkinson’s disease, will offer a convenience advantage over generic COMT inhibitors. The company will delay launch due to pandemic and manufacturing issues.
Mylan/Theravance’s Yupelri Will Launch Late This Year To Address COPD Niche
Yupelri was approved by the US FDA as the first nebulized long-acting muscarinic antagonist for once-daily treatment of chronic obstructive pulmonary disease.